Chronic respiratory disease therapeutic agent and cardiac fibrillation suppressing composition

A technology for respiratory diseases and cardiac fibrosis, applied in respiratory diseases, cardiovascular diseases, drug combinations, etc., can solve the problems of induced myocardial damage, dosage dependence, etc., and achieve improvement of morbidity, inhibition of pulmonary or cardiac fibrosis , excellent pharmacological activity and biological adaptability

Inactive Publication Date: 2018-01-02
NIPPON HYPOX LAB INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, anthracycline-based anticancer agents represented by doxorubicin have a serious side effect of inducing myocardial damage in a dose-dependent manner.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chronic respiratory disease therapeutic agent and cardiac fibrillation suppressing composition
  • Chronic respiratory disease therapeutic agent and cardiac fibrillation suppressing composition
  • Chronic respiratory disease therapeutic agent and cardiac fibrillation suppressing composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] 1. Study on the effect on pulmonary fibrosis induced by bleomycin

[0083] Bleomycin is used to make disease model animals of interstitial pneumonia. The bleomycin was administered to male SD rats aged 10 weeks after birth, and the 2,3,5-hydroquinone derivative represented by the above general formula (1) of the present invention was administered. The effects of trimethylhydroquinone-1-hexyl ether (HTHQ) were investigated. The composition of the test group is as follows: control group: administration of sterilized normal saline, test group 1: single administration of bleomycin (7.5mg / kg body weight), test group 2: combined administration of bleomycin (7.5mg / kg body weight). kg body weight) and HTHQ (50 mg / kg body weight / day), test group 3: combined administration of bleomycin (7.5 mg / kg body weight) and HTHQ (200 mg / kg body weight / day).

[0084] Regarding the test groups 1 to 3, the bleomycin was administered once, and the administration was performed orally. In addi...

Embodiment 2

[0101] 2. Research on the effect on lung inflammation induced by tobacco smoke

[0102] Six-week-old SPF C57BL / 6N male mice weighing 20 to 25 g were purchased from Coretec Co., Ltd. (Korea). After a quarantine and acclimatization period of about 1 week, the mice were divided into 5 groups as shown in Table 2 below.

[0103] [Table 2]

[0104]

[0105] The test was carried out as follows. In the test group, the COPD (chronic obstructive pulmonary disease) model group was exposed to tobacco smoke (8 cigarettes / day) for 1 hour for 10 days, and the intranasal LPS was administered (5 µg / 50 µL / mouse). For the positive control substance administration group, 10 mg / kg body weight / day of roflumilast as a positive control substance was orally administered for 10 days, followed by exposure to tobacco smoke for 1 hour after 1 hour. In addition, LPS (5 µg / 50 µL / mouse) was intranasally administered on the 8th day from the start of the test. Here, roflumilast is a selective phosphodi...

Embodiment 3

[0114] 3. Research on the effect on asthma

[0115] The effectiveness of the hydroquinone derivative represented by the above general formula (1) of the present invention on asthma was investigated using an allergic asthma model in mice sensitized with ovalbumin.

[0116] 6-week-old BALB / c female mice were purchased, and after about 2 weeks of acclimatization and feeding, the mice were allocated 5 mice in each of the 5 groups shown in Table 3 below.

[0117] [table 3]

[0118]

[0119] test to Figure 12 The indicated sensitization, elicitor and test substance dosing schedules were performed. Figure 12 "IP" in "IP" indicates ovalbumin sensitization treatment by intraperitoneal administration of ovalbumin / aluminum hydroxide, "IH" indicates inhalation exposure treatment of ovalbumin, and "PO" indicates administration of each test substance. Specifically, 200 μL of PBS (pH 7.4) emulsified by adding 20 μg of ovalbumin and 2 mg of aluminum hydroxide as an adjuvant was intrap...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A novel drug is provided which is effective in the prevention and treatment of chronic respiratory disease such as COPD, interstitial pneumonia and asthma. This chronic respiratory disease therapeuticagent contains, as the active ingredient, a hydroquinone derivative represented by general expression (1) (In the expression, R1 indicates an alkyl group of 4-8 carbon atoms, R2 represents a hydrogenatom, an alkyl carbonyl group of 2-6 carbon atoms, or an alkoxycarbonyl group of 2-6 carbon atoms.).

Description

technical field [0001] The present invention relates to a therapeutic agent for chronic respiratory diseases, a food composition for preventing or improving chronic respiratory diseases, a composition for inhibiting cardiac fibrosis, and a composition for alleviating side effects of drugs, which contain specific hydroquinone derivatives as active ingredients. Background technique [0002] Chronic respiratory diseases are non-infectious chronic diseases of trachea and lung tissue, and major chronic respiratory diseases include chronic obstructive pulmonary disease (COPD), asthma, and interstitial pneumonia. Among them, chronic obstructive pulmonary disease (COPD) is mainly an inflammatory disease of the lungs caused by long-term inhalation of harmful substances such as tobacco smoke and polluted air, showing progressive airflow obstruction. The morbidity and mortality of COPD are at a high level in the world (the fourth leading cause of death in the world, WHO survey, 2004), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/085A61P9/00A61P11/00A61P11/06A61P43/00
CPCA61K31/085A61K31/222A61P9/00A61P11/00A61P11/06A61P29/00A61P43/00A23L33/10A23V2002/00A23V2200/314
Inventor 三木德太郎西川洋史姜钟求杉山理
Owner NIPPON HYPOX LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap